Why Two People With the Same BMI Face Very Different Heart Failure Risks
Inflammation and blood sugar levels that deviate from what BMI predicts can dramatically shift heart failure risk, even at identical body weights.
Summary
BMI alone doesn't tell the whole story of heart failure risk. A large UK Biobank study of nearly 400,000 people found that individuals whose inflammation markers or blood sugar levels were higher than expected for their BMI faced dramatically elevated heart failure risk — up to twice as high in women. Conversely, those with unexpectedly adverse lipid profiles showed lower risk than predicted. This challenges the idea that body weight is the primary driver of cardiovascular danger and suggests that metabolic phenotyping — looking beyond BMI to specific biomarkers — could help identify who truly needs aggressive heart failure prevention. The findings point toward more personalized, precision-based risk stratification rather than relying on weight alone.
Detailed Summary
Heart failure affects millions worldwide, and obesity is widely recognized as a major contributing factor. But body mass index — the standard tool for measuring obesity — masks enormous variation in metabolic health. Two people at the same BMI can have wildly different inflammatory states, blood sugar regulation, and lipid profiles, leading to very different disease outcomes. This study set out to quantify exactly how much that variation matters for heart failure risk.
Researchers analyzed data from 394,198 UK Biobank participants over a median follow-up of 12.3 years. Using a data-driven clustering approach, they classified participants into subgroups based on whether their cardiometabolic biomarkers — including CRP, blood glucose, blood pressure, lipids, and liver enzymes — were higher or lower than what would be expected given their BMI. Cox proportional hazards models then assessed how these discordant profiles related to incident heart failure.
The results were striking. Men whose CRP or blood glucose was unexpectedly high for their BMI had 59% and 39% higher heart failure risk, respectively. Women showed even sharper divergence — 103% higher risk for discordant inflammation and 80% higher for discordant hyperglycemia. Paradoxically, discordantly adverse lipid profiles were associated with lower heart failure risk, possibly reflecting confounding by statin use or metabolic compensatory mechanisms. Discordant liver transaminase levels showed no significant association.
These findings matter clinically because they suggest BMI-based risk stratification misclassifies a meaningful proportion of patients. Someone who appears metabolically average by weight alone may harbor a highly inflammatory or dysglycemic phenotype that puts them at substantially elevated heart failure risk.
Caveats include the observational design, which cannot establish causality. The analysis relies on abstract-level detail, so nuances of biomarker measurement timing, medication use, and subgroup definitions remain unclear. Findings may not generalize beyond predominantly White European populations in the UK Biobank.
Key Findings
- Elevated CRP beyond what BMI predicts raises heart failure risk by 59% in men and 103% in women.
- Discordantly high blood glucose raises heart failure risk by 39% in men and 80% in women.
- Paradoxically, unexpectedly adverse lipid profiles were linked to lower heart failure risk.
- BMI alone misclassifies metabolic risk — biomarker phenotyping improves heart failure prediction.
- Sex differences were significant: women showed consistently higher risk amplification from metabolic discordance.
Methodology
Prospective cohort study using 394,198 UK Biobank participants followed for a median of 12.3 years. A data-driven clustering method identified subgroups where cardiometabolic biomarkers deviated from BMI-expected levels. Cox proportional hazards models adjusted for confounders assessed heart failure incidence defined by ICD-10 codes.
Study Limitations
The observational design precludes causal inference, and confounders such as statin use may explain paradoxical lipid findings. The UK Biobank population is predominantly White and European, limiting generalizability. This summary is based on the abstract only, so full methodological details, covariate adjustments, and subgroup definitions could not be evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.